First licensed treatment for hidradenitis suppurativa

The licence for Humira (adalimumab) has been extended to include the treatment of active moderate to severe hidradenitis suppurativa (HS) in adults who have had an inadequate response to conventional HS therapy

HS is a painful, chronic systemic inflammatory disorder, characterised by inflamed nodules, boils and abscesses located particularly around the groin and underarm.
‘The approval of Humira to treat moderate to severe HS is a major step forward in supporting patients with this distressing and life-changing condition,’ said Dr David Fitzgerald, consultant dermatologist at Salford Royal NHS Foundation Trust. ‘Patients with HS can experience immense pain and the condition often dramatically affects their psychological wellbeing and quality of life.’
The benefits and risks of long-term treatment should be regularly evaluated and if treatment is interrupted, Humira may be reintroduced at the maintenance dose of 40mg per week.
Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases